Clinical Trial Update: A Study to Assess the Effectiveness of Second-Line Therapy of Upadacitinib and Risankizumab in Adult Participants With Crohn's Disease in a Real-World Setting

View source ↗

Summary

A real-world study evaluating the effectiveness of second-line therapy with upadacitinib and risankizumab in adults with Crohn's disease; the trial is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Risankizumab (risankizumab)
• Upadacitinib (upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Crohn's Disease | Status: RECRUITING